Rivka Riven Kreitman

Summary

Publications

  1. ncbi request reprint On the horizon: possible neuroprotective role for glatiramer acetate
    Rivka Riven Kreitman
    Teva Neuroscience, 1090 Horsham Road, North Wales, PA 19454 1090, USA
    Mult Scler 10:S81-6; discussion S86-9. 2004
  2. doi request reprint Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Aaron Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mult Scler 14:494-9. 2008

Detail Information

Publications2

  1. ncbi request reprint On the horizon: possible neuroprotective role for glatiramer acetate
    Rivka Riven Kreitman
    Teva Neuroscience, 1090 Horsham Road, North Wales, PA 19454 1090, USA
    Mult Scler 10:S81-6; discussion S86-9. 2004
    ..Additional research is needed to determine if these promising neuroprotective effects correlated with the long-term effect of GA in MS...
  2. doi request reprint Long-term (up to 22 years), open-label, compassionate-use study of glatiramer acetate in relapsing-remitting multiple sclerosis
    Aaron Miller
    Mount Sinai School of Medicine, New York, NY, USA
    Mult Scler 14:494-9. 2008
    ..0 reached EDSS >or= 6.0. Adverse events were similar to those reported in short-term clinical trials. This study shows a low rate of relapses and EDSS progression in RRMS patients on GA for up to 22 years...